LLS Urges Blood Cancer Patients to get Vaccinated as its National Patient Registry Enters Next Phase in COVID-19 Vaccine StudiesPosted On: July 15, 2021
Rye Brook, N.Y., July 15, 2021—The Leukemia & Lymphoma Society® (LLS) began recruitment this week for a new study evaluating T-cell immune response to COVID-19 vaccine among people with a current or past diagnosis of blood cancer. This invitation-only follow-up study will include a sub-set of participants from a larger LLS study examining COVID-19 spike antibody response to vaccination. Read More
Please send all media-related inquiries and interview requests to firstname.lastname@example.org. An LLS representative will respond as soon as possible.